Who is the parent company of Eisai Corporation?

Eisai Inc. (pronounced ā-zī) is a U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd, a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.

Where is Eisai inc.located in New Jersey?

Established in 1995, Eisai Inc. began marketing its first product in the United States in 1997 and has rapidly grown to become an integrated pharmaceutical business. Headquartered in Woodcliff Lake, New Jersey, we are dedicated to a tradition of genuine concern for people and are driven by the desire to help meet the diverse health care needs…

What makes Eisai a good company to work for?

In the United States, our rapid growth and strong performance result from putting patients and their families first when making decisions and from empowering the people who manage our operations. Eisai employees personify our values of integrity, respect, professionalism, quality and teamwork.

When did Eisai come to the United States?

Welcome to Eisai Inc. Eisai Inc. (pronounced ā-zī) is a U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd, a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Established in 1995, Eisai Inc. began marketing its first product in the United States in 1997…

What is the drug code for Eisai e2027?

Development Code: E2027 Indications / Drug class: Treatment for dementia with Lewy bodies / PDE 9 inhibitor In-house Description: A selective phosphodiesterase (PDE) 9 inhibitor, which reduces the degradation of cyclic GMP which is critical to signal transmission among cells.

Where are the headquarters of Eisai pharmaceutical company?

Eisai Inc. is established as a pharmaceutical sales subsidiary in New Jersey, the United States. Eisai Ltd. is established as a pharmaceutical sales subsidiary in London, the United Kingdom. Eisai Deutschland GmbH is established as a pharmaceutical sales subsidiary in Frankfurt, Germany.

Why is e7820 a unique angiogenesis inhibitor?

E7820 is a unique angiogenesis inhibitor with antitumor activities. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.